Mayo Clinic Laboratories Serology Test Has Emergency Use Authorization
Mayo Clinic Laboratories is now offering a new serology test with Emergency Use Authorization (EUA). This test is used to identify the presence of an immune response to SARS-CoV-2, the virus that causes COVID-19.
Current clients who were ordering the previous serology test (Test ID: COR2G) will be transitioned to the new test (Test ID: VCOV2). Please reach out to your local representative with questions.
The serology testing is intended only to detect antibodies to the virus, not to diagnose recent or active infection, and it cannot pinpoint the date of exposure. The development of an IgG antibody response to SARS-CoV-2 takes time. While some individuals become seropositive between 8 and 14 days post-symptom onset, over 95% are positive after day 14. As a result, this testing is only advised to be performed on individuals at least 10 days after initial symptom onset or at least 10 days after a known exposure. Importantly, some individuals, particularly those who are immunosuppressed, may never develop a detectable immune response (i.e., antibodies).
As a trusted partner, Mayo Clinic Laboratories remains committed to providing timely, accurate test results that inform optimal patient care despite the unprecedented challenges all of us in health care continue to face.